Oncolytic virus treatment differentially affects the CD56
NK cells
cell cycle
immunotherapy
lymphocyte trafficking
natural killer cells
oncolytic virus
proliferation
reovirus
Journal
Immunology
ISSN: 1365-2567
Titre abrégé: Immunology
Pays: England
ID NLM: 0374672
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
02
07
2021
accepted:
10
01
2022
pubmed:
15
2
2022
medline:
20
4
2022
entrez:
14
2
2022
Statut:
ppublish
Résumé
Natural killer (NK) cells protect against intracellular infection and cancer. These properties are exploited in oncolytic virus (OV) therapy, where antiviral responses enhance anti-tumour immunity. We have analysed the mechanism by which reovirus, an oncolytic dsRNA virus, modulates human NK cell activity. Reovirus activates NK cells in a type I interferon (IFN-I) dependent manner, inducing STAT1 and STAT4 signalling in both CD56
Identifiants
pubmed: 35156714
doi: 10.1111/imm.13453
pmc: PMC10357483
doi:
Substances chimiques
Antiviral Agents
0
CD56 Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
104-120Informations de copyright
© 2022 The Authors. Immunology published by John Wiley & Sons Ltd.
Références
Int J Cancer. 2013 May 15;132(10):2327-38
pubmed: 23114986
Sci Transl Med. 2012 Jun 13;4(138):138ra77
pubmed: 22700953
Nature. 1996 Jul 11;382(6587):171-4
pubmed: 8700208
J Gen Virol. 2013 Nov;94(Pt 11):2367-2392
pubmed: 23999164
J Exp Med. 2009 Oct 26;206(11):2469-81
pubmed: 19808259
Nat Rev Immunol. 2015 Apr;15(4):231-42
pubmed: 25790790
J Immunol. 2002 Oct 15;169(8):4279-87
pubmed: 12370359
Mol Ther. 2014 Jul;22(7):1320-1332
pubmed: 24695102
Nat Immunol. 2008 May;9(5):495-502
pubmed: 18425106
Nat Rev Drug Discov. 2019 Sep;18(9):689-706
pubmed: 31292532
Annu Rev Immunol. 2020 Apr 26;38:759-784
pubmed: 32340572
Immunol Rev. 2019 Jan;287(1):202-225
pubmed: 30565241
Nature. 2011 Apr 28;472(7344):481-5
pubmed: 21478870
Science. 2011 Jan 7;331(6013):44-9
pubmed: 21212348
Microbes Infect. 2011 Apr;13(4):291-302
pubmed: 21256242
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Mol Ther. 2019 Jun 5;27(6):1139-1152
pubmed: 31053413
Oncogene. 1998 Jan 15;16(2):217-25
pubmed: 9464540
Mol Ther Methods Clin Dev. 2020 Jan 15;17:349-358
pubmed: 32071927
Mol Ther. 2008 Jan;16(1):146-53
pubmed: 18071337
Nat Rev Cancer. 2016 Mar;16(3):131-44
pubmed: 26911188
mBio. 2011 Aug 09;2(4):
pubmed: 21828218
J Exp Med. 1994 Oct 1;180(4):1395-403
pubmed: 7523571
Nat Immunol. 2001 Oct;2(10):951-6
pubmed: 11550009
Cancers (Basel). 2020 Oct 31;12(11):
pubmed: 33142841
EMBO J. 1998 Jun 15;17(12):3351-62
pubmed: 9628872
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33741729
Nat Rev Immunol. 2008 May;8(5):362-71
pubmed: 18379575
Virology. 2013 Jan 5;435(1):37-45
pubmed: 23217614
Mol Ther Oncolytics. 2020 Oct 04;20:434-446
pubmed: 33665363
N Engl J Med. 1989 Jun 29;320(26):1731-5
pubmed: 2543925
J Allergy Clin Immunol. 2013 Sep;132(3):515-525
pubmed: 23993353
Nucleic Acids Res. 2013 Jan;41(Database issue):D1040-6
pubmed: 23203888
Eur J Immunol. 2001 Nov;31(11):3138-46
pubmed: 11745330
J Exp Med. 2007 Jun 11;204(6):1349-58
pubmed: 17502662
J Exp Med. 2016 Feb 8;213(2):225-33
pubmed: 26755706
J Immunol. 2012 Jul 1;189(1):211-21
pubmed: 22649192
PLoS Biol. 2017 Dec 18;15(12):e2004086
pubmed: 29253856
Gut. 2018 Mar;67(3):562-573
pubmed: 27902444
Crit Rev Biochem Mol Biol. 2017 Dec;52(6):638-662
pubmed: 28799433
Cancer Res. 2012 Apr 1;72(7):1651-60
pubmed: 22315352
Immunology. 2022 May;166(1):104-120
pubmed: 35156714
Nature. 2006 Mar 23;440(7083):540-4
pubmed: 16525420
Nat Med. 2012 Dec;18(12):1827-34
pubmed: 23178246
PLoS One. 2011;6(9):e25060
pubmed: 21966414
Science. 1998 Nov 13;282(5392):1332-4
pubmed: 9812900
Nat Med. 2002 Oct;8(10):1145-52
pubmed: 12244301
Immunobiology. 2017 Jan;222(1):11-20
pubmed: 26264743
J Virol. 2018 May 14;92(11):
pubmed: 29540598
Nat Immunol. 2004 Dec;5(12):1260-5
pubmed: 15531883
Front Immunol. 2014 Apr 23;5:187
pubmed: 24795729
Viruses. 2019 Oct 17;11(10):
pubmed: 31627371
Vaccine. 2009 Sep 18;27(41):5543-9
pubmed: 19647065
Clin Exp Immunol. 2015 Apr;180(1):98-107
pubmed: 25469725
Blood. 2003 Apr 15;101(8):3052-7
pubmed: 12480696
Trends Immunol. 2001 Nov;22(11):633-40
pubmed: 11698225
Cell Rep. 2017 Aug 29;20(9):2251-2261
pubmed: 28854372
J Virol. 1996 Jan;70(1):612-6
pubmed: 8523580
Nat New Biol. 1972 May 24;237(73):120-1
pubmed: 4503851
Lancet. 1981 Oct 24;2(8252):891-3
pubmed: 6170850
Annu Rev Virol. 2019 Sep 29;6(1):567-584
pubmed: 31283436
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33046622
Leukemia. 2015 Sep;29(9):1799-810
pubmed: 25814029
Nat Rev Immunol. 2005 May;5(5):375-86
pubmed: 15864272
Cancer Res. 2007 Mar 15;67(6):2840-8
pubmed: 17363607
Curr Opin Virol. 2011 Dec;1(6):497-512
pubmed: 22180766
Sci Transl Med. 2018 Jan 3;10(422):
pubmed: 29298869
J Exp Med. 2011 Jan 17;208(1):13-21
pubmed: 21173105
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nat Immunol. 2019 Dec;20(12):1574-1583
pubmed: 31745335
J Immunol. 2004 Feb 1;172(3):1455-62
pubmed: 14734722
J Immunother Cancer. 2019 Jul 1;7(1):164
pubmed: 31262361
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14725-32
pubmed: 21825173
Nat Immunol. 2007 Dec;8(12):1337-44
pubmed: 17965716
Nat Rev Immunol. 2011 Aug 26;11(10):645-57
pubmed: 21869816
Proc Natl Acad Sci U S A. 1972 Mar;69(3):721-5
pubmed: 4501586
Nature. 2009 Jan 29;457(7229):557-61
pubmed: 19136945
Nat Rev Immunol. 2018 Aug;18(8):498-513
pubmed: 29743717
J Immunol. 1999 Oct 15;163(8):4473-80
pubmed: 10510389
Blood. 2012 Nov 1;120(18):3718-28
pubmed: 22968462
Nat Commun. 2017 Nov 6;8(1):1320
pubmed: 29105654
Blood. 2016 Sep 15;128(11):1475-89
pubmed: 27465917
Annu Rev Immunol. 2014;32:513-45
pubmed: 24555472
J Immunol. 2008 Feb 1;180(3):1592-7
pubmed: 18209055
Nat Med. 2002 Oct;8(10):1153-60
pubmed: 12244302
Cell Host Microbe. 2012 Oct 18;12(4):571-84
pubmed: 23084923